- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04946981
Recovery and Muscle Function After Supplementation With Turmeric (RECOFAST)
December 9, 2022 updated by: Naturex SA
A Placebo Controlled, Randomised, Crossover Clinical Trial to Evaluate the Effect of Turmipure Gold® in Muscle Pain and Function Recovery in Moderately Active Adults
The objective of the study is to test the capacity of a five-day supplementation of Turmipure Gold® to improve exercise-induced muscle pain and function recovery in moderately active adults after exercise-induced muscle damage
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cork, Ireland, T23 R50R
- Atlantia Food Clinical Trials
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy free-living males
- Age: 25-45 years old
- Have a BMI between 18.5 and 28 kg/m²
- Moderately active with running 15-20 km per week
- With 1 to 4h of training per week, with maximum 1h of lower body heavy-load or resistance training (e.g., Hill running or hiking, HIT exercise, Squats, Lunges, Leg-press, Bench steps, etc.)
- Consent to the study protocol and to comply with study product
- Willing to limit caffeine, smoking, and alcohol consumption during the entire study period with no more than 5 cigarettes per day and 2 drinks. Also, alcohol consumption will not be allowed 24hours prior to exercise-induced muscular damage
- Willing to refrain from training for 3 days before the first test, 5 days before each damage-inducing exercise and during each supplementation phase, including active recovery exercises such as swimming, cycling at low intensity, unusual distance walking (however such should be encouraged during the 14 days wash-out)
- Willing to refrain the use of anti-inflammatory/pain reliever drugs such as paracetamol, NSAIDs, etc., during each supplementation phase, from 24 hours prior to 72 hours following the exercise-induced muscular damage
Willing to refrain from 'recovery' treatments over the 72 hours following the damage inducing exercise such as:
- Hydrotherapy - cold water immersion, hot water immersion, or contrast therapy (as well as Jacuzzis, Steam baths, or Saunas)
- Massage - self, foam rolling, etc.
- Stretching
- Compression garments
- Topical applications - Tiger Balm, Deep Heat etc.
Exclusion Criteria:
- Participants with any indicators of arthritis, joint disorders chronic pain syndrome, muscle disorder diseases (e.g., fibromyalgia, etc.)
- History of surgery or significant injury in joints or in the lower limb in the last six months prior to study enrolment, or an anticipated need for surgical or invasive procedure that will be performed during the study
- Using omega-3-fatty acid, probiotic supplements, vitamins, minerals, or any dietary supplements (including botanicals), especially to maintain joint health 4 weeks prior to screening and during the entire study. Potential supplements include but are not limited to Beta-alanine, Creatine, HMB, Carnosine, Taurine, androstenedione, DHEA, Whey protein, or a pre-workout supplement
- Following any specific diet such as high-protein, vegetarian, vegan, etc
- Taking any drugs such as antibiotics, laxatives, or immunosuppressant drugs
- History of glucocorticoid injection or hyaluronic acid injections within 3 months prior to enrolment
- Participants near or in the peak of training for an athletic race (half or marathon, cycling tour or triathlon)
- History or current significant cardiovascular, pulmonary, renal, liver, digestive (including an inflammatory bowel disease), infectious disease, systemic disease, immune disorder, or metabolic/endocrine disorders (including diabetes mellitus) or other disease that would preclude supplement ingestion and/or assessment of study objectives, including uncontrolled hypertension, uncontrolled thyroidism or lipidaemia that is not on stable medication for at least 3 months.
- Participant has any concurrent medical or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements
- Participant with history of drug and / or alcohol abuse at the time of enrolment
- Any previous or current cancer diagnosis (including a benign or malign tumour of intestine or colon)
- Current illnesses which could interfere with the study (e.g., prolonged severe diarrhoea, regurgitation/severe, difficulty swallowing)
- Known allergy to components of the test product or sensitivity to herbal products or with a medical history of food allergies
- Participants taking any anticoagulant or heparin treatment (including aspirin)
- Clinically significant abnormal laboratory results at screening
- Participant currently involved in any other clinical trial or having participated in a trial within 90 days prior to randomisation.
- Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
- History of non-compliance with medical treatments or recommendations.
- Participants who are required to perform squatting motions or descend a lot of stairs in their daily work activities, which may be painful following the Exercise Induced Muscle Damage.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Randomized Crossover_Sequence 1
Participants who meet the eligibility criteria will be randomized and will receive first the experimental product Turmipure GOLD® during the first study phase and then the placebo control during the second study phase.
Both study phases are separated by a washout period of minimum 14 days.
|
TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
Placebo: colored acacia gum - 1 capsule per day - as prescribed
|
|
Other: Randomized Crossover_Sequence 2
Participants who meet the eligibility criteria will be randomized and will receive first the placebo control during the first study phase and then the experimental product Turmipure GOLD® during the second study phase.
Both study phases are separated by a washout period of minimum 14 days.
|
TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
Placebo: colored acacia gum - 1 capsule per day - as prescribed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on Perceived Muscle Soreness
Time Frame: 72 hours
|
Perceived Muscle Soreness in quadriceps during squatting activities assessed by VAS (0-100 mm, after two tries)
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on Muscle damage
Time Frame: 72 hours
|
Muscle damage assessed by circulating levels of Creatine kinase in blood samples
|
72 hours
|
|
Change on Isometric Muscle function recovery
Time Frame: 72 hours
|
Muscle function recovery assessed on quadriceps muscular function during isometric contractions recording the torque (Nm) using Biodex
|
72 hours
|
|
Change on Isokinetic Muscle function recovery
Time Frame: 72 hours
|
Muscle function recovery assessed on quadriceps muscular function during isokinetic extensions recording the torque (Nm) using Biodex
|
72 hours
|
|
Change on Muscle power recovery
Time Frame: 72 hours
|
Muscle power recovery assessed by Peak power (Watts) using vertical jump tests (best performance and average of 3 tries)
|
72 hours
|
|
Change on Muscle ROM recovery
Time Frame: 72 hours
|
Muscle ROM recovery assessed by Range Of Movement using a goniometer (knee flexion)
|
72 hours
|
|
Change on Perceived wellness and well-being
Time Frame: 72 hours
|
Perceived wellness and well-being is assessed by a psychometric test evaluating fatigue, sleep quality, general muscle soreness, stress, and mood (0-25, 25 indicating best feelings of wellness and well-being)
|
72 hours
|
|
Change on Perceived exertion during exercise
Time Frame: 30 min
|
Perceived exertion through breathing difficulty during exercise assessed by the Borg Rating of Perceived Exertion (0-10, 10 indicating maximal difficulty)
|
30 min
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Trevor Wood, PhD, Sport Physiologist University College Cork
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 12, 2021
Primary Completion (Actual)
April 1, 2022
Study Completion (Actual)
April 1, 2022
Study Registration Dates
First Submitted
June 21, 2021
First Submitted That Met QC Criteria
June 30, 2021
First Posted (Actual)
July 1, 2021
Study Record Updates
Last Update Posted (Estimate)
December 12, 2022
Last Update Submitted That Met QC Criteria
December 9, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFCRO-128
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Boston Scientific CorporationRecruitingLow Back Pain | Chronic Pain | Chronic Low-back Pain | Leg Pain | Intractable Pain | Chronic Leg PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Qi's ClinicNot yet recruitingNon-Cancer Pain,Musculoskeletal Pain,Chronic Pain,Acute Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
noiVita SrlsUniversity of Eastern PiedmontCompletedCervical Pain | Pain Management | Lumbar Pain | Muscular | Chronic Pain (Back / Neck)Italy
-
Chinese University of Hong KongNot yet recruitingPain, Acute | Chronic Post Operative Pain | Pain, ChronicHong Kong
-
University of SaskatchewanRoyal University Hospital FoundationCompletedPain | Pain, Acute | Pain, Chronic | Pain, IntractableCanada
-
Kyowa Kirin Co., Ltd.Completed
Clinical Trials on Turmipure Gold®
-
Naturex SABioFortisCompletedLiver Function | Gastrointestinal Tolerance | Kidney FunctionFrance
-
Naturex SAAtlantia Food Clinical TrialsCompleted
-
Naturex SAArtialis; Vizera d.o.o.CompletedJoint Pain | Knee DiscomfortCroatia, Slovenia
-
Okan UniversityMedical Park Hospital IstanbulCompletedLow Back Pain | Connective Tissue Defect (Diagnosis)Turkey
-
Naturex SABiofortis Mérieux NutriSciencesCompleted
-
Medipol UniversityRecruitingPostoperative Pain | Trismus | Postoperative Edema | Orthognathic SurgeryTurkey
-
Ain Shams UniversityCompletedCesarean Section Complications | Caffeine | Postoperative IleusEgypt
-
Vedic Lifesciences Pvt. Ltd.Not yet recruiting
-
NestléCompletedStool CompositionPhilippines
-
Harran UniversityCompletedPost Operative Pain | Chronic Apical Periodontitis of Pulpal OriginTurkey (Türkiye)